Recs

0

Gen-Probe Shares Popped: What You Need to Know

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of diagnostic-test maker Gen-Probe (Nasdaq: GPRO  ) rocketed up today, gaining as much as 20% in intraday trading on heavier-than-average volume.

So what: Bloomberg reported today that Gen-Probe has hired investment bank Morgan Stanley (NYSE: MS  ) to manage a sale process and noted that bids are expected in the next couple of weeks. The article suggested that Novartis (NYSE: NVS  ) , Thermo Fisher Scientific (NYSE: TMO  ) , Danaher (NYSE: DHR  ) , and Life Technologies (Nasdaq: LIFE  ) could be among the bidders.

Now what: As I noted yesterday with InterMune, this kind of news tends to get traders and short-term investors very excited. However, speculation on potential buyouts can often end in disappointment if nothing ever pans out. Longer-term investors would be well-advised to continue focusing on the prospects for Gen-Probe as a stand-alone company and leave the rumors to the traders.

Want to keep up to date on these stocks?

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Thermo Fisher Scientific is a Motley Fool Inside Value recommendation. Novartis AG is a Motley Fool Global Gains pick. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Matt Koppenheffer does not have a financial interest in any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or on his RSS feed. The Fool's disclosure policy prefers dividends over a sharp stick in the eye.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 1484359, ~/Articles/ArticleHandler.aspx, 5/26/2012 7:07:03 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 9 hours ago Sponsored by:
DOW 12,454.83 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
NASD 2,837.53 -1.85 -0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/25/2012 4:00 PM
GPRO $81.19 Down -0.01 -0.01%
Gen-Probe, Inc. CAPS Rating: ***
NVS $51.96 Up +0.23 +0.44%
Novartis CAPS Rating: *****
TMO $51.68 Down -0.53 -1.02%
Thermo Fisher Scie… CAPS Rating: *****
MS $13.25 Down -0.06 -0.45%
Morgan Stanley CAPS Rating: ***
DHR $52.76 Down -0.07 -0.13%
Danaher Corp CAPS Rating: ****
LIFE $41.83 Down -0.18 -0.43%
Life Technologies… CAPS Rating: ****

Advertisement